Immunogenicity and Safety of Bivalent Recombinant Protein COVID-19 Vaccine ZF2202: A Randomized, Open-label, Positive-controlled Trial
In this randomized, open-label, positive-controlled trial, eligible participants were allocated to four cohorts: Cohort #1, Cohort #2, Cohort #3, and Cohort #4. Prior to allocation, participants in Cohort #1 and Cohort #2 had received two doses of the inactivated vaccine BBIBP-CorV; those in Cohort #3 had received three doses of the inactivated vaccine BBIBP-CorV; and those in Cohort #4 had received three doses of the recombinant protein vaccine ZF2001. During the trial, participants in Cohort #1 were administered a single dose of the inactivated vaccine BBIBP-CorV, whereas participants in the other cohorts received a single dose of the bivalent recombinant protein vaccine ZF2202. Immunogenicity against Delta, BA.2, and BA.5 subvariants was assessed on day 14 post-vaccination.
Results
A total of 272 participants were enrolled and allocated to Cohort #1 (N=61), Cohort #2 (N=61), Cohort #3 (N=75), and Cohort #4 (N=75). On day 14 post-vaccination, the geometric mean titers (GMTs) of neutralizing antibodies against the Delta variant increased 14.9-fold, 98.8-fold, 25.8-fold, and 62.8-fold, respectively, across these cohorts. For the BA.2 subvariant, the GMTs increased 6.1, 38.5, 32.7, and 100.1 times, respectively. For the BA.5 subvariant, the GMTs increased 2.7, 14.2, 15.2, and 28.1 times, respectively. Within 28 days after vaccination, the incidences of adverse reactions were 41.7%, 31.2%, 37.3%, and 57.3%, respectively. No serious adverse event and adverse event resulted in withdrawal or death occurred.